Intersect ENT Company Profile (NASDAQ:XENT)

About Intersect ENT (NASDAQ:XENT)

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Industry, Sector and Symbol:

Sector: Medical
Industry: Medical Equipment, Supplies & Distribution
Sub-Industry: N/A
Symbol: NASDAQ:XENT
CUSIP: N/A
Web: www.intersectent.com

Capitalization:

Market Cap: $868.37 million
Outstanding Shares: 29,189,000

Average Prices:

50 Day Moving Avg: $30.56
200 Day Moving Avg: $24.46
52 Week Range: $7.65 - $33.25

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -76.28
P/E Growth: -2.40

Sales & Book Value:

Annual Revenue: $87.16 million
Price / Sales: 9.96
Book Value: $3.88 per share
Price / Book: 7.67

Profitability:

EBIDTA: ($19,710,000.00)
Net Margins: -22.94%
Return on Equity: -17.60%
Return on Assets: -15.64%

Debt:

Current Ratio: 9.81%
Quick Ratio: 9.17%

Misc:

Average Volume: 304,505 shs.
Beta: 0.73
Short Ratio: 2.34

Frequently Asked Questions for Intersect ENT (NASDAQ:XENT)

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) issued its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.11. The firm had revenue of $24 million for the quarter, compared to the consensus estimate of $22.62 million. Intersect ENT had a negative net margin of 22.94% and a negative return on equity of 17.60%. The company's revenue for the quarter was up 24.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.21) EPS. View Intersect ENT's Earnings History.

When will Intersect ENT make its next earnings announcement?

Intersect ENT is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Intersect ENT.

Where is Intersect ENT's stock going? Where will Intersect ENT's stock price be in 2017?

10 analysts have issued 12-month price objectives for Intersect ENT's stock. Their predictions range from $14.00 to $40.00. On average, they expect Intersect ENT's share price to reach $27.11 in the next year. View Analyst Ratings for Intersect ENT.

What are analysts saying about Intersect ENT stock?

Here are some recent quotes from research analysts about Intersect ENT stock:

1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (7/26/2017)
2. Northland Securities analysts commented, "We remain bullish on the takeout potential of this story. Key Points As a reminder, RESOLVE would be in an office" setting, hence would not be subject to the facility payment pressures currently being witnessed by PROPEL on the Medicare front. It is our understanding that the company would advocate the use of an unlisted J-code (physician administered drug) immediately after NDA approval." (3/13/2017)

Who are some of Intersect ENT's key competitors?

Some companies that are related to Intersect ENT include CONMED Corporation (CNMD), MiMedx Group (MDXG), OraSure Technologies (OSUR), Asante Solutions (PUMP), Cardiovascular Systems (CSII), K2M Group Holdings (KTWO), Orthofix International N.V. (OFIX), AtriCure (ATRC), CryoLife (CRY), Landauer (LDR), Meridian Bioscience (VIVO), Consort Medical plc (CSRT), Invacare Corporation (IVC), Antares Pharma (ATRS), Exactech (EXAC), STAAR Surgical Company (STAA), Sientra (SIEN) and Utah Medical Products (UTMD).

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the folowing people:

Lisa D. Earnhardt, President, Chief Executive Officer, Director
Jeryl L. Hilleman, Chief Financial Officer
Richard E. Kaufman, Senior Vice President, Chief Operating Officer
David A. Lehman, General Counsel
Gwen Carscadden, Chief People Officer
Kieran T. Gallahue, Lead Director
Teresa L. Kline, Director
William Anthony Vernon, Director
Cynthia L. Lucchese, Independent Director
Dana G. Mead Jr., Independent Director

Who owns Intersect ENT stock?

Intersect ENT's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (7.93%), FMR LLC (5.12%), Federated Investors Inc. PA (4.20%), Vanguard Group Inc. (3.94%), Alliancebernstein L.P. (3.22%) and Neuberger Berman Group LLC (2.57%). Company insiders that own Intersect ENT stock include Amy Wolbeck, Frederic H Moll, James Stambaugh, Jeryl L Hilleman, Kieran Gallahue, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.

Who sold Intersect ENT stock? Who is selling Intersect ENT stock?

Intersect ENT's stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Neuberger Berman Group LLC, Federated Investors Inc. PA, Paulson & CO. Inc., Thrivent Financial For Lutherans, Candriam Luxembourg S.C.A., Kopp Investment Advisors LLC and Penn Capital Management Co. Inc.. Company insiders that have sold Intersect ENT stock in the last year include Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.

Who bought Intersect ENT stock? Who is buying Intersect ENT stock?

Intersect ENT's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Alliancebernstein L.P., Lord Abbett & CO. LLC, EAM Investors LLC, State Street Corp, Citigroup Inc., Numeric Investors LLC and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Intersect ENT.

How do I buy Intersect ENT stock?

Shares of Intersect ENT can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intersect ENT's stock price today?

One share of Intersect ENT stock can currently be purchased for approximately $29.75.

MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)

Community Ranking:		3.6 out of 5 ( )
Outperform Votes:		226 (Vote Outperform)
Underperform Votes:		87 (Vote Underperform)
Total Votes:		313

MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Intersect ENT (NASDAQ:XENT) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	2 Hold Ratings, 8 Buy Ratings
Consensus Rating:	Buy (Score: 2.80)
Consensus Price Target:	$27.11 (8.87% downside)

Analysts' Ratings History for Intersect ENT (NASDAQ:XENT)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/13/2017	Canaccord Genuity	Boost Price Target	Buy	$32.00 -> $37.00	Low
9/11/2017	Bank of America Corporation	Boost Price Target	Buy	$33.00 -> $40.00	High
8/22/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$35.00	Low
8/2/2017	Deutsche Bank AG	Set Price Target	Buy	$27.00 -> $31.00	High
8/2/2017	Northland Securities	Reiterated Rating	Hold	$25.00	High
5/10/2017	William Blair	Reiterated Rating	Outperform		Low
5/3/2017	Wedbush	Boost Price Target	Outperform -> Outperform	$25.00 -> $26.00	High
12/6/2016	Guggenheim	Initiated Coverage	Buy	$20.00	N/A
11/4/2016	Leerink Swann	Reiterated Rating	Outperform	$21.00 -> $14.00	N/A
11/2/2016	J P Morgan Chase & Co	Downgrade	Overweight -> Neutral	$25.00 -> $16.00	N/A
8/4/2016	BTIG Research	Reiterated Rating	Hold	$14.00	N/A
3/24/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$29.00	N/A
10/2/2015	Sterne Agee CRT	Reiterated Rating	Buy	$37.00	N/A

(Data available from 9/24/2015 forward)

Earnings History for Intersect ENT (NASDAQ:XENT)

Earnings by Quarter for Intersect ENT (NASDAQ:XENT)

Earnings History by Quarter for Intersect ENT (NASDAQ XENT)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/31/2017		($0.20)					N/A
8/1/2017	Q2 2017	($0.19)	($0.08)	$22.62 million	$24.00 million	View	Listen
5/2/2017	Q1 2017	($0.25)	($0.23)	$19.39 million	$20.47 million	View	Listen
2/28/2017	Q416	($0.20)	($0.17)	$23.47 million	$24.20 million	View	Listen
11/2/2016	Q316	($0.27)	($0.22)	$17.80 million	$18.50 million	View	N/A
8/2/2016	Q216	($0.26)	($0.21)	$18.91 million	$19.30 million	View	N/A
5/5/2016	Q116	($0.29)	($0.29)	$16.92 million	$16.69 million	View	N/A
2/23/2016	Q415	($0.25)	($0.20)	$18.36 million	$18.80 million	View	Listen
11/4/2015	Q315	($0.29)	($0.35)	$14.80 million	$14.20 million	View	N/A
8/5/2015	Q215	($0.26)	($0.23)	$14.74 million	$15.20 million	View	N/A
5/6/2015	Q115	($0.33)	($0.23)	$13.00 million	$13.37 million	View	N/A
2/26/2015	Q414	($0.29)	($0.16)	$12.20 million	$13.40 million	View	N/A
11/5/2014	Q314	($0.35)	($0.32)	$8.20 million	$9.10 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Intersect ENT (NASDAQ:XENT)

2017 EPS Consensus Estimate: ($0.77)
2018 EPS Consensus Estimate: ($0.48)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	3	($0.26)	($0.22)	($0.24)
Q2 2017	3	($0.19)	($0.19)	($0.19)
Q3 2017	3	($0.26)	($0.17)	($0.21)
Q4 2017	3	($0.17)	($0.06)	($0.13)
Q1 2018	1	($0.16)	($0.16)	($0.16)
Q2 2018	1	($0.12)	($0.12)	($0.12)
Q3 2018	1	($0.14)	($0.14)	($0.14)
Q4 2018	1	($0.06)	($0.06)	($0.06)

(Data provided by Zacks Investment Research)

Dividend History for Intersect ENT (NASDAQ:XENT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Intersect ENT (NASDAQ:XENT)

Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 83.12%

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/15/2017	Lisa D Earnhardt	Insider	Sell	20,000	$30.19	$603,800.00
9/5/2017	Jeryl L Hilleman	CFO	Sell	12,833	$31.05	$398,464.65
8/28/2017	Richard E Kaufman	COO	Sell	22,425	$30.22	$677,683.50
8/15/2017	Lisa D Earnhardt	Insider	Sell	20,000	$30.79	$615,800.00
8/4/2017	Jeryl L Hilleman	CFO	Sell	12,833	$29.00	$372,157.00
7/25/2017	Richard E Kaufman	COO	Sell	12,500	$28.25	$353,125.00
7/17/2017	Lisa D Earnhardt	Insider	Sell	20,000	$29.03	$580,600.00
7/10/2017	Jeryl L Hilleman	CFO	Sell	12,835	$27.18	$348,855.30
6/15/2017	Lisa D Earnhardt	Insider	Sell	20,000	$26.10	$522,000.00
5/22/2017	Richard E Kaufman	COO	Sell	20,000	$22.87	$457,400.00
5/15/2017	Lisa D Earnhardt	Insider	Sell	20,000	$22.98	$459,600.00
4/20/2017	Richard E Kaufman	COO	Sell	1,250	$17.25	$21,562.50
4/17/2017	Lisa D Earnhardt	Insider	Sell	20,000	$16.06	$321,200.00
3/15/2017	Lisa D Earnhardt	Insider	Sell	20,000	$15.02	$300,400.00
10/20/2016	Richard E Kaufman	COO	Sell	3,603	$16.58	$59,737.74
10/17/2016	Lisa D Earnhardt	Insider	Sell	400	$18.00	$7,200.00
9/7/2016	Amy Wolbeck	VP	Sell	28,664	$15.83	$453,751.12
9/6/2016	James Stambaugh	VP	Sell	4,000	$16.00	$64,000.00
8/3/2016	James Stambaugh	VP	Sell	3,977	$17.00	$67,609.00
7/18/2016	James Stambaugh	VP	Sell	5,000	$15.33	$76,650.00
6/13/2016	James Stambaugh	VP	Sell	500	$14.38	$7,190.00
5/16/2016	Kieran Gallahue	Director	Buy	8,000	$12.64	$101,120.00
4/27/2016	Amy Wolbeck	VP	Sell	2,000	$20.01	$40,020.00
4/20/2016	Richard E Kaufman	COO	Sell	3,603	$18.86	$67,952.58
4/18/2016	Lisa D Earnhardt	CEO	Sell	28,500	$18.69	$532,665.00
3/21/2016	Richard E Kaufman	COO	Sell	3,603	$16.51	$59,485.53
3/15/2016	Lisa D Earnhardt	CEO	Sell	9,000	$18.01	$162,090.00
3/14/2016	Frederic H Moll	Director	Sell	1,299	$18.53	$24,070.47
3/8/2016	Frederic H Moll	Director	Sell	601	$18.56	$11,154.56
2/22/2016	Richard E Kaufman	COO	Sell	3,603	$18.65	$67,195.95
1/21/2016	Richard E. Kaufman	COO	Sell	7,206	$17.93	$129,203.58
1/15/2016	Lisa D. Earnhardt	CEO	Sell	12,500	$19.26	$240,750.00
12/15/2015	Lisa D Earnhardt	CEO	Sell	6,820	$19.85	$135,377.00
11/16/2015	Lisa D Earnhardt	CEO	Sell	6,818	$18.00	$122,724.00
10/15/2015	Lisa D Earnhardt	CEO	Sell	6,818	$18.72	$127,632.96
9/15/2015	Lisa D Earnhardt	CEO	Sell	6,818	$25.99	$177,199.82
9/11/2015	Frederic H Moll	Director	Sell	10,000	$25.21	$252,100.00
8/17/2015	Lisa D Earnhardt	CEO	Sell	6,818	$28.51	$194,381.18
7/20/2015	James Stambaugh	VP	Sell	12,000	$30.52	$366,240.00
7/15/2015	Lisa D Earnhardt	CEO	Sell	19,318	$29.62	$572,199.16
6/15/2015	Lisa D Earnhardt	CEO	Sell	19,318	$29.30	$566,017.40
5/8/2015	James Stambaugh	VP	Sell	2,785	$23.87	$66,477.95
4/13/2015	Amy Wolbeck	VP	Sell	16,000	$26.25	$420,000.00
4/1/2015	James Stambaugh	VP	Sell	8,343	$25.50	$212,746.50
3/16/2015	Lisa D Earnhardt	Insider	Sell	19,318	$23.56	$455,132.08
3/11/2015	Amy Wolbeck	VP	Sell	8,000	$23.06	$184,480.00
3/9/2015	James Stambaugh	VP	Sell	8,343	$23.02	$192,055.86
2/17/2015	Lisa D Earnhardt	Insider	Sell	19,318	$22.69	$438,325.42
2/12/2015	Amy Wolbeck	VP	Sell	8,000	$22.12	$176,960.00
2/2/2015	James Stambaugh	VP	Sell	8,343	$20.98	$175,036.14
1/26/2015	Robert H Binney Jr	VP	Sell	6,300	$21.18	$133,434.00
9/11/2014	Cynthia L Lucchese	Director	Buy	5,000	$17.11	$85,550.00

(Data available from 1/1/2013 forward)

Headline Trends for Intersect ENT (NASDAQ:XENT) Latest Headlines for Intersect ENT (NASDAQ:XENT)

Source:

Date	Headline
	Intersect ENT, Inc. breached its 50 day moving average in a Bearish Manner : XENT-US : September 21, 2017 finance.yahoo.com - September 23 at 12:13 PM
	Intersect ENT, Inc. – Value Analysis (NASDAQ:XENT) : September 22, 2017 finance.yahoo.com - September 23 at 12:13 PM
	Intersect ENT, Inc. (XENT) Insider Lisa D. Earnhardt Sells 20,000 Shares www.americanbankingnews.com - September 19 at 10:24 PM
	Zacks: Brokerages Expect Intersect ENT, Inc. (XENT) Will Announce Quarterly Sales of $21.48 Million www.americanbankingnews.com - September 15 at 4:55 AM
	Canaccord Genuity Reiterates "Buy" Rating for Intersect ENT, Inc. (XENT) www.americanbankingnews.com - September 13 at 3:34 PM
	Analysts Issue Forecasts for Intersect ENT, Inc.'s Q3 2017 Earnings (XENT) www.americanbankingnews.com - September 13 at 7:42 AM
	Intersect ENT (XENT) Reports Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety ... - StreetInsider.com www.streetinsider.com - September 12 at 12:30 PM
	Intersect ENT, Inc. (XENT) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - September 12 at 3:06 AM
	Intersect ENT, Inc. (XENT) Price Target Increased to $40.00 by Analysts at Bank of America Corporation www.americanbankingnews.com - September 11 at 8:22 AM
	Intersect ENT Announces Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and ... - Business Wire (press release) www.businesswire.com - September 10 at 9:59 AM
	Intersect ENT Announces Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant finance.yahoo.com - September 10 at 9:59 AM
	Jeryl L. Hilleman Sells 12,833 Shares of Intersect ENT, Inc. (XENT) Stock www.americanbankingnews.com - September 6 at 8:26 PM
	Intersect ENT, Inc. (XENT) COO Sells $677,683.50 in Stock www.americanbankingnews.com - August 29 at 7:18 PM
	Intersect ENT, Inc. (XENT) Earns Buy Rating from Piper Jaffray Companies www.americanbankingnews.com - August 22 at 4:28 PM
	Intersect ENT, Inc. (XENT) Given Consensus Recommendation of "Buy" by Analysts www.americanbankingnews.com - August 18 at 2:42 PM
	Insider Selling: Intersect ENT, Inc. (XENT) Insider Sells 20,000 Shares of Stock www.americanbankingnews.com - August 17 at 7:38 PM
	ETFs with exposure to Intersect ENT, Inc. : August 14, 2017 finance.yahoo.com - August 15 at 8:31 AM
	Zacks: Analysts Anticipate Intersect ENT, Inc. (NASDAQ:XENT) Will Post Quarterly Sales of $21.52 Million www.americanbankingnews.com - August 9 at 7:20 AM
	-$0.20 Earnings Per Share Expected for Intersect ENT, Inc. (NASDAQ:XENT) This Quarter www.americanbankingnews.com - August 7 at 6:26 PM
	FY2017 EPS Estimates for Intersect ENT, Inc. Raised by William Blair (NASDAQ:XENT) www.americanbankingnews.com - August 4 at 10:00 AM
	Intersect ENT, Inc. Forecasted to Post Q3 2017 Earnings of ($0.26) Per Share (NASDAQ:XENT) www.americanbankingnews.com - August 4 at 7:16 AM
	Q3 2017 EPS Estimates for Intersect ENT, Inc. Decreased by Analyst (XENT) www.americanbankingnews.com - August 4 at 7:16 AM
	Leerink Swann Equities Analysts Lift Earnings Estimates for Intersect ENT, Inc. (NASDAQ:XENT) www.americanbankingnews.com - August 3 at 4:40 PM
	Intersect ENT Reports Second Quarter 2017 Results - Business Wire (press release) www.businesswire.com - August 3 at 9:05 AM
	Edited Transcript of XENT earnings conference call or presentation 1-Aug-17 8:30pm GMT finance.yahoo.com - August 3 at 9:05 AM
	Intersect ENT, Inc. (XENT) Cut to "Hold" at BidaskClub www.americanbankingnews.com - August 2 at 5:12 PM
	Intersect ENT, Inc. (NASDAQ:XENT) Stock Rating Reaffirmed by Canaccord Genuity www.americanbankingnews.com - August 2 at 4:38 PM
	Intersect ENT, Inc. (XENT) Stock Rating Reaffirmed by Northland Securities www.americanbankingnews.com - August 2 at 2:02 PM
	Investor Network: Intersect ENT Inc to Host Earnings Call finance.yahoo.com - August 2 at 8:54 AM
	Intersect ENT Reports Second Quarter 2017 Results finance.yahoo.com - August 2 at 8:54 AM
	Intersect ENT reports 2Q loss finance.yahoo.com - August 2 at 8:54 AM
	Intersect ENT, Inc. (NASDAQ:XENT) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS www.americanbankingnews.com - August 1 at 10:46 PM
	ETFs with exposure to Intersect ENT, Inc. : July 31, 2017 finance.yahoo.com - August 1 at 8:01 AM
	Intersect Looks To Boost Position In ENT Implant Market, Driving Stock Up seekingalpha.com - July 29 at 8:51 AM
	Richard E. Kaufman Sells 12,500 Shares of Intersect ENT, Inc. (NASDAQ:XENT) Stock www.americanbankingnews.com - July 26 at 8:00 PM
	Intersect ENT, Inc. (XENT) Upgraded by Zacks Investment Research to "Hold" www.americanbankingnews.com - July 26 at 11:59 AM
	Intersect ENT, Inc. (NASDAQ:XENT) Downgraded by BidaskClub to "Buy" www.americanbankingnews.com - July 25 at 2:15 PM
	Intersect ENT, Inc. (NASDAQ:XENT) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - July 24 at 2:27 PM
	Teresa L. Kline Joins Intersect ENT's Board of Directors \| Business ... - Business Wire (press release) www.businesswire.com - July 21 at 8:52 AM
	Teresa L. Kline Joins Intersect ENT’s Board of Directors finance.yahoo.com - July 21 at 8:51 AM
	Zacks: Analysts Expect Intersect ENT, Inc. (XENT) Will Announce Quarterly Sales of $22.65 Million www.americanbankingnews.com - July 20 at 11:54 AM
	Insider Selling: Intersect ENT, Inc. (NASDAQ:XENT) Insider Sells 20,000 Shares of Stock www.americanbankingnews.com - July 18 at 7:25 PM
	Analysts Expect Intersect ENT, Inc. (XENT) to Announce -$0.19 Earnings Per Share www.americanbankingnews.com - July 18 at 2:42 PM
	Intersect ENT to Report Second Quarter 2017 Financial Results www.businesswire.com - July 15 at 9:46 AM
	ETFs with exposure to Intersect ENT, Inc. : July 12, 2017 finance.yahoo.com - July 13 at 11:17 AM
	Intersect ENT, Inc. (NASDAQ:XENT) CFO Sells $348,855.30 in Stock www.americanbankingnews.com - July 12 at 8:17 PM
	Intersect ENT, Inc. (XENT) Downgraded to "Sell" at Zacks Investment Research www.americanbankingnews.com - July 9 at 6:38 PM
	Commit To Buy Intersect ENT At $22.50, Earn 15.7% Annualized Using Options www.nasdaq.com - July 8 at 8:54 AM
	ETFs with exposure to Intersect ENT, Inc. : June 27, 2017 finance.yahoo.com - June 28 at 3:32 AM
	Intersect ENT, Inc. (XENT) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - June 27 at 2:56 PM